small molecule

LYTGOBI

FUTIBATINIB

Loss of exclusivityNovember 2039latest FDA-listed patent expiry

CompanyTaiho Oncology →View the full company profile on CliffBio

Drug detail

Brand name	LYTGOBI
Active ingredient	FUTIBATINIB
Strength	4MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	September 2022
Marketing status	RX

Listed patents

Patent	Expires	Type
11833151	November 2039	product
10434103	March 2036	substance, product
9108973	February 2033	substance, product

Regulatory exclusivity

Code	Expires
ODE-410	September 2029
NCE	September 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Taiho Oncology